期刊文献+

乳腺癌分子分型的临床病理表现分析 被引量:2

Analysis on Clinical Pathological Manifestation of the Molecular Typing of Breast Cancer
下载PDF
导出
摘要 目的探讨乳腺癌不同分子分型的临床病理表现,为疾病诊治提供参考。方法回顾性分析2016年1月—2017年12月我院收治的124例乳腺癌患者的临床资料,观察患者乳腺癌分子分型情况及不同分子分型的临床病理特征。结果患者中,管腔A型39.52%,管腔B型30.65%,Her-2亚型12.90%,基底亚型13.71%。分子分型同肿瘤大小、腋窝淋巴结转移状况及TNM分期差异有统计学意义(P<0.05)。结论乳腺癌分子分型能够为乳腺癌临床诊治及预后评估提供有价值的依据。 Objective To analyze the clinical pathological features of different molecular types of breast cancer, to provide reference for clinical diagnosis and treatment. Methods The clinical data of 124 patients with breast cancer in our hospital from January 2016 to December 2017 were retrospectively analyzed. The molecular typing of breast cancer and clinical pathological characteristics of different molecular typing were observed. Results In the patients, the lumen A type accounted for 39.52%, the lumen B type accounted for 30.65%, the Her-2 subtype accounted for 12.90%,and the basal subtype accounted for 13.71%. The molecular typing was signifcantly different from the tumor size, axillary lymph node metastasis and TNM staging (P 〈 0.05). Conclusion The molecular classifcation of breast cancer can provide a valuable basis for the diagnosis and treatment of breast cancer and the prognosis evaluation.
作者 童晶 丁岚
出处 《中国继续医学教育》 2018年第7期54-56,共3页 China Continuing Medical Education
关键词 乳腺癌 分子分型 临床病理 特征 breast cancer molecular typing clinical pathological characteristics
  • 相关文献

参考文献9

二级参考文献82

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 2Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 3Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.
  • 4Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 5The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 6Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 7Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 8北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 9Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 10Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.

共引文献327

同被引文献24

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部